Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 19k
5 July 2018
E-001439/2018(ASW)
Answer given by First Vice-President Timmermans on behalf of the Commission
Question reference: E-001439/2018

The Commission refers the Honourable Member to its reply to Written Question E-000040/2017, which details the Commission's various initiatives as regards tackling corruption in the healthcare sector in the framework of the EU anti-corruption experience-sharing programme and the European semester of economic governance.

The Commission supports Member States in their efforts to fight against corruption through, for example, technical assistance and facilitation of experience-sharing of best practices(1).

More specifically as regards Greece, the economic adjustment programme monitors the implementation of the national strategy against corruption, taking into consideration particular needs in high risk sectors such as national health services.

As regards the Novartis case, the Commission would like to recall that when allegations of corruption arise, competent national authorities are responsible for investigating them.

The Commission cannot intervene in these investigations. Moreover, on the basis of the Treaties on which the European Union is founded, the Commission has no competence to set up a committee of inquiry to follow-up on allegations of corruption.

(1)https://ec.europa.eu/home-affairs/what-we-do/policies/organised-crime-and-human-trafficking/corruption_en

Last updated: 5 July 2018Legal notice